2nd Edition of International Cancer Research Conference
March 19-21, 2026 | Singapore
Targeted Oncology
Targeted oncology, a promising field within cancer research, focuses on treatments tailored to individual patients based on their genetic makeup, tumor characteristics, and other factors. This personalized approach offers the potential for more effective and less toxic therapies compared to traditional treatments. Targeted therapies often involve drugs that specifically target molecules involved in cancer growth and progression, such as certain proteins or genetic mutations. Advancements in genomics and molecular biology have facilitated the development of these therapies, allowing oncologists to better match treatments to the unique molecular profiles of patients' tumors. As research in targeted oncology continues to evolve, it holds great promise for improving outcomes and quality of life for cancer patients.
Rajvir Dahiya
University of California San Francisco, United States
Anyou Wang
DIFIBER LLC, United States
Michael Thompson
University of Toronto, Canada
Paulo Cesar De Morais
Catholic University of Brasilia, Brazil
Shilpa S Dhar
UT MD Anderson Cancer Center, United States
Eleni Petsalaki
University of Crete, Greece
Can Küçük
Dokuz Eylul University, TurkeySubmit your abstract Today
Title : A novel blood-based mRNA genomics technology for cancer diagnosis and treatment
Rajvir Dahiya, University of California San Francisco, United States
Title : Uncovering tumor-suppressive roles of histone modifiers in gastric cancer through spatial transcriptomics and epigenomics
Shilpa S Dhar, UT MD Anderson Cancer Center, United States
Title : Unveiling the synergism of radiofrequency therapy and graphene nanocomposite in tumor cell viability assay
Paulo Cesar De Morais, Catholic University of Brasilia, Brazil
Title : A case-based approach using IMPeTUs criteria in FDG PET/CT reporting of multiple myeloma
Mudalsha Ravina, All India Institute of Medical Sciences, India
Title : Updates on controversies surrounding the staging and management of newly diagnosed localized prostate cancer using prostate-specific membrane antigen (PSMA) positron emission tomography
Patricia Tai, University of Saskatchewan, Canada
Title : A pioneering, first-of-its-kind Canadian off-site program designed to reduce the burden on hospital staff and optimize the use of space
Patricia Tai, University of Saskatchewan, Canada